[Department of Error] Department of Error
Heier JS, Kherani S, Desai S, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet 2017; 390: 50–61—In figure 1 of this Article, the one patient in cohort 3 that withdrew consent did so after 1 year. Table 1 reports median BCVA data over two rows (ETDRS letter score and Snellen equivalent) with range in parentheses. An error has been corrected in paragraph 6 of the results and should read “…but five of ten patients in cohorts 4 and 5 who received an injection of 2×1010 vg…”.